Chromosomal microarray is still the gold standard method as recommended by ACMG Guidelines as the 1st line testing for constitutional disorders. Unfortunately, most array platforms on the market are outdated having been designed more than a decade ago. BioDiscovery has partnered with Illumina to design a modern SNP array that offers significantly improved exon-level coverage of disease-associated genes at a low cost combined with NxClinical, the leading comprehensive variant interpretation software, to create a unique and powerful solution. Learn more about this modern CMA and its applicability for prenatal, postnatal, reproductive, and cancer genetics in this 30-minute webinar presented by Dan Saul, Customer Success Manager at BioDiscovery.
May 11, 2021